Research programme: multiple sclerosis therapeutic - Mapi Pharma
Latest Information Update: 22 Sep 2014
At a glance
- Originator Mapi Pharma
- Class Polymers
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple sclerosis
Most Recent Events
- 22 Sep 2014 Preclinical trials in Multiple sclerosis in Israel (unspecified route)